Clinical profile of Parkinson's disease in the Gumei community of Minhang district, Shanghai
AUTOR(ES)
Liu, Kangyong, Gu, Zhaohua, Dong, Liang, Shen, Liwei, Sun, Yinyi, Zhang, Ting, Shi, Nan, Zhang, Qian, Zhang, Wei, Zhao, Meizhen, Sun, Xiaojiang
FONTE
Clinics
DATA DE PUBLICAÇÃO
2014-07
RESUMO
OBJECTIVE:We examined the demographic and clinical profiles of Parkinson's disease in Shanghai, China, to assist in disease management and provide comparative data on Parkinson's disease prevalence, phenotype, and progression among different regions and ethnic groups.METHODS:A door-to-door survey and follow-up clinical examinations identified 180 community-dwelling Han-Chinese Parkinson's disease patients (104 males, 76 females).RESULTS:The average age at onset was 65.16±9.60 years. The most common initial symptom was tremor (112 patients, 62.22%), followed by rigidity (38, 21.11%), bradykinesia (28, 15.56%) and tremor plus rigidity (2, 1.11%). Tremor as the initial symptom usually began in a single limb (83.04% of patients). The average duration from onset to mild Parkinson's disease (Hoehn-Yahr phase 1-2) was 52.74±45.64 months. Progression from mild to moderate/severe Parkinson's disease (phase≥3) was significantly slower (87.07±58.72 months; p<0.001), except for patients presenting initially with bradykinesia (53.83±24.49 months). Most patients (149/180, 82.78%) took levodopa with or without other drugs. The Hamilton Anxiety Scale revealed symptoms of clinical anxiety in 35 patients, and the Hamilton Depression Scale revealed depressive symptoms in 88 patients. The depressed or anxious subgroup (123 patients) demonstrated a significantly younger age at onset (55.54±7.68 years) compared with the overall mean (p<0.05).CONCLUSION:Unilateral limb tremor was the most common initial symptom, and motor function deteriorated slowly over ≅4−9 years. Earlier-onset patients experience greater psychiatric dysfunction.
Documentos Relacionados
- Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.
- The reliability of clinical assessment of Parkinson's disease.
- Community care for patients with idiopathic Parkinson's disease.
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease.
- Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.